open access

Vol 15, No 1 (2020)
Original Papers
Published online: 2020-02-27
Get Citation

Impact of atrial fibrillation on natural history and treatment of heart failure — a multicentre registry study

Radosław Bartkowiak, Iwona Gorczyca, Beata Wożakowska-Kapłon, Maciej Kluk
DOI: 10.5603/FC.2020.0004
·
Folia Cardiologica 2020;15(1):11-18.

open access

Vol 15, No 1 (2020)
Original Papers
Published online: 2020-02-27

Abstract

Introduction. When heart failure (HF) and atrial fibrillation (AF) afflict the same patient simultaneously, it becomes a challenge for cardiologists. This is not only due to the need to intensify preventive measures to reduce the prevalence of common aetiological factors, but also due to growing healthcare costs, particularly care costs for elderly patients at high risk of accumulated complications of both diseases. Our study was aimed at evaluating the concomitant incidence of AF on the natural history and treatment of Polish HF patients on the basis of data obtained in a multicentre registry study. Material and methods. In this study, the population subjected to retrospective analysis consisted of Polish patients included in the long-term ESC-HF registry study (N = 1,126). A comparative analysis of the study group (AF+) and the control group (AF−) was carried out. Results. No differences were observed in the rates of in-hospital deaths between the (AF+) and the (AF−) group: 2.9% versus 2.8%, [p = not significant (NS)]. The average duration of hospitalisation in the AF+ group was 9.8 ± 14.7 days compared to 8.8 ± 10.9 days in the AF− group (p = NS). In the AF+ group, compared to the AF− group, significantly higher frequencies were recorded for the following parameters: exacerbation of chronic HF as the cause of hospitalisation, intravenous diuretics usage during hospitalisation, electrical cardioversion, as well as in-hospital use of mineralocorticoid receptor antagonists, diuretics, digoxin, oral antithrombotic agents and amiodarone. Conclusions. In the population of HF patients requiring hospitalisation, the AF+ subgroup is characterised by poorer clinical condition (biventricular cardiac decompensation, lower systolic blood pressure, higher heart rate on admission, and more frequent use of intravenous diuretics). The concomitance of AF significantly impacts the natural history and treatment of HF patients.

Abstract

Introduction. When heart failure (HF) and atrial fibrillation (AF) afflict the same patient simultaneously, it becomes a challenge for cardiologists. This is not only due to the need to intensify preventive measures to reduce the prevalence of common aetiological factors, but also due to growing healthcare costs, particularly care costs for elderly patients at high risk of accumulated complications of both diseases. Our study was aimed at evaluating the concomitant incidence of AF on the natural history and treatment of Polish HF patients on the basis of data obtained in a multicentre registry study. Material and methods. In this study, the population subjected to retrospective analysis consisted of Polish patients included in the long-term ESC-HF registry study (N = 1,126). A comparative analysis of the study group (AF+) and the control group (AF−) was carried out. Results. No differences were observed in the rates of in-hospital deaths between the (AF+) and the (AF−) group: 2.9% versus 2.8%, [p = not significant (NS)]. The average duration of hospitalisation in the AF+ group was 9.8 ± 14.7 days compared to 8.8 ± 10.9 days in the AF− group (p = NS). In the AF+ group, compared to the AF− group, significantly higher frequencies were recorded for the following parameters: exacerbation of chronic HF as the cause of hospitalisation, intravenous diuretics usage during hospitalisation, electrical cardioversion, as well as in-hospital use of mineralocorticoid receptor antagonists, diuretics, digoxin, oral antithrombotic agents and amiodarone. Conclusions. In the population of HF patients requiring hospitalisation, the AF+ subgroup is characterised by poorer clinical condition (biventricular cardiac decompensation, lower systolic blood pressure, higher heart rate on admission, and more frequent use of intravenous diuretics). The concomitance of AF significantly impacts the natural history and treatment of HF patients.
Get Citation

Keywords

heart failure, atrial fibrillation, treatment, clinical outcome, registry

About this article
Title

Impact of atrial fibrillation on natural history and treatment of heart failure — a multicentre registry study

Journal

Folia Cardiologica

Issue

Vol 15, No 1 (2020)

Pages

11-18

Published online

2020-02-27

DOI

10.5603/FC.2020.0004

Bibliographic record

Folia Cardiologica 2020;15(1):11-18.

Keywords

heart failure
atrial fibrillation
treatment
clinical outcome
registry

Authors

Radosław Bartkowiak
Iwona Gorczyca
Beata Wożakowska-Kapłon
Maciej Kluk

References (20)
  1. Kirchhof P, Benussi S, Kotecha D, et al. [2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS] [Article in Polish]. Kardiol Pol. 2016; 74: 1359–1469.
  2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22(8): 983–988.
  3. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995; 98(5): 476–484.
  4. Stewart S, Hart CL, Hole DJ, et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002; 113(5): 359–364.
  5. Furberg CD, Psaty BM, Manolio TA, et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 1994; 74(3): 236–241.
  6. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285(18): 2370–2375.
  7. Pruszczyk P, Stepinska J, Banasiak W, et al. Zastosowanie nowych doustnych leków przeciwkrzepliwych w prewencji powikłań zatorowych u chorych z migotaniem przedsionków. Kardiol Pol. 2012; 70: 979–988.
  8. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998; 98(10): 946–952.
  9. Ponikowski P, Voors AA, Anker SD, et al. [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure] [Article in Polish]. Kardiol Pol. 2016; 74: 1037–1147.
  10. Rywik TM, Kołodziej P, Targoński R, et al. Characteristics of the heart failure population in Poland: ZOPAN, a multicentre national programme. Kardiol Pol. 2011; 69(1): 24–31.
  11. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol. 2003; 91(6A): 2D–8D.
  12. McManus DD, Shaikh AY, Abhishek F, et al. Atrial fibrillation and heart failure parallels: lessons for atrial fibrillation prevention. Crit Pathw Cardiol. 2011; 10(1): 46–51.
  13. Wodchis WP, Bhatia RS, Leblanc K, et al. A review of the cost of atrial fibrillation. Value Health. 2012; 15(2): 240–248.
  14. Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation. 2009; 119(18): 2516–2525.
  15. Dahlström U, Filippatos G, Maggioni A, et al. ESC Heart Failure Association. Heart Failure Pilot protocol. Eur Heart J. 2010; 31(18): 2184–2186.
  16. Maggioni AP, Anker SD, Dahlström U, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry. Euro J Heart Fail. 2014; 15(10): 1173–1184.
  17. Ozierański K, Kapłon-Cieślicka A, Peller M, et al. Clinical characteristics and predictors of one-year outcome of heart failure patients with atrial fibrillation compared to heart failure patients in sinus rhythm. Kardiol Pol. 2016; 74(3): 251–261.
  18. Kasprzak JD, Stepinska J, Wozakowska-Kaplon B, et al. Optymalna częstość rytmu serca — aktualny cel terapii kardiologicznej. Stanowisko grupy ekspertów Sekcji Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Kardiol Pol. 2012; 70: 1081–1094.
  19. Niewinski P, Ponikowski P. Niewydolność serca — postępy 2014/2015. Medycyna Praktyczna, wydanie specjalne Kardiologia. 2014; 3: 16–23.
  20. Sosnowska-Pasiarska B, Bartkowiak R, Wożakowska-Kapłon B, et al. Population of Polish patients participating in the Heart Failure Pilot Survey (ESC-HF Pilot). Kardiol Pol. 2013; 71(3): 234–240.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl